SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that on October 5, 2026, it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market.
This development matters because it signals a potential shift in the U.S. surgical robotics landscape, which has long been dominated by a few major players. The SSi Mantra is designed to be a cost-effective alternative, and its entry could increase competition, potentially driving down prices and expanding access to robotic-assisted surgery. Robotic surgery offers benefits such as smaller incisions, reduced pain, and faster recovery times compared to traditional open surgery. However, its high cost has limited widespread adoption. By aiming to make robotic surgery more affordable, SS Innovations could help more hospitals and patients benefit from this technology.
The SSi Mantra system features 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient information. It also includes a virtual real-time image of the robotic patient side arm carts and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the standard surgeon command center, intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.
For the healthcare industry, the FDA's decision could influence the competitive dynamics of the surgical robotics market. If approved, the SSi Mantra would offer an alternative to existing systems, potentially pressuring competitors to innovate or reduce costs. For patients, it could mean greater access to minimally invasive surgery, which often leads to better outcomes and shorter hospital stays. Hospitals may also benefit from lower capital and operational costs, making robotic surgery more feasible for smaller or resource-constrained facilities.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. For more information, visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
To view the full press release, visit https://ibn.fm/A6dJ8. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer. View the original release on www.newmediawire.com.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These statements are based on information available as of the date hereof, and all parties undertake no duty to update this information unless required by law.
